The store will not work correctly when cookies are disabled.
2,3-Di-thiophen-2-yl-quinoxaline-6,7-diol
ID: ALA190039
PubChem CID: 135964360
Max Phase: Preclinical
Molecular Formula: C16H10N2O2S2
Molecular Weight: 326.40
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Oc1cc2nc(-c3cccs3)c(-c3cccs3)nc2cc1O
Standard InChI: InChI=1S/C16H10N2O2S2/c19-11-7-9-10(8-12(11)20)18-16(14-4-2-6-22-14)15(17-9)13-3-1-5-21-13/h1-8,19-20H
Standard InChI Key: DKWQFKCOHCSXOM-UHFFFAOYSA-N
Molfile:
RDKit 2D
22 25 0 0 0 0 0 0 0 0999 V2000
2.7667 0.0208 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7542 0.8500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0500 -0.4000 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.0417 1.2583 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.3292 0.8375 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3292 0.0083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4667 1.2708 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4792 -0.3917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6167 -0.4042 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6125 1.2458 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0958 0.8333 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0958 0.0083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2250 0.9458 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
3.5750 -1.2125 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
3.5417 2.0958 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2292 -0.0500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3792 -1.3750 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7667 1.5583 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7875 -0.6542 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3542 2.2708 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8125 1.2458 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.8083 -0.4042 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 1 2 0
4 2 2 0
5 6 1 0
6 3 1 0
7 2 1 0
8 1 1 0
9 6 2 0
10 5 2 0
11 12 2 0
12 9 1 0
13 7 1 0
14 8 1 0
15 7 2 0
16 8 2 0
17 14 1 0
18 13 1 0
19 16 1 0
20 15 1 0
21 11 1 0
22 12 1 0
17 19 2 0
4 5 1 0
18 20 2 0
11 10 1 0
M END
Associated Targets(Human)
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 326.40 | Molecular Weight (Monoisotopic): 326.0184 | AlogP: 4.50 | #Rotatable Bonds: 2 |
Polar Surface Area: 66.24 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 7.56 | CX Basic pKa: 0.70 | CX LogP: 4.31 | CX LogD: 4.09 |
Aromatic Rings: 4 | Heavy Atoms: 22 | QED Weighted: 0.53 | Np Likeness Score: -0.63 |
References
1. Székelyhidi Z, Pató J, Wáczek F, Bánhegyi P, Hegymegi-Barakonyi B, Erös D, Mészáros G, Hollósy F, Hafenbradl D, Obert S, Klebl B, Kéri G, Orfi L.. (2005) Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives., 15 (13): [PMID:15925511] [10.1016/j.bmcl.2005.04.064] |